This is an important step forward in the fight against a serious public health problem, hospital-acquired infections, stated Jack McMaken, president and CEO of AcryMed. There are 2 million hospital-acquired infections annually in this country, with 90,000 resulting in death. About half of these infections are associated with catheters and other percutaneous devices that provide a support surface for organisms to track into deeper tissue. A typical infection can cost as much as $47,000 per patient to treat. Our SilvaGard treatment provides a legitimate solution to many of these hospital related, life threatening infections by preventing the formation of biofilms on medical devices.
SilvaGard is a new technology developed by AcryMed that is based on years of work with silver antimicrobial applications. AcryMeds SilvaSorb® wound dressings and SilvaSorb gel are recognized worldwide in the advanced wound-care industry.